• Ocular Therapeutix Inc., of Bedford, Mass, reported initial results of its sustained-release travoprost-loaded punctum plug feasibility study to treat glaucoma. Read More
• Mylan Inc., of Pittsburgh, reported that its subsidiary Mylan Pharmaceuticals Inc. received FDA approval for its generic version of Janssen Pharmaceutical Inc.'s Sporanox (itraconazole), indicated for the treatment of fungal infections that begin in the lungs in patients who are intolerant of or refractory to amphotericin B therapy. Read More
• Sucampo Pharmaceuticals Inc., of Bethesda, Md., and Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, said they filed a supplemental new drug application seeking approval to expand the use of Amitiza (lubiprostone) for treating opioid-induced constipation in patients with chronic, noncancer pain. Read More
Regeneron Pharmaceuticals Inc. stormed onto the wet age-related macular degeneration (AMD) market with second quarter sales of Eylea (aflibercept injection) increasing 57 percent compared to their first quarter. The drug competes with Roche AG's Lucentis (ranibizumab) and off-label use from Avastin (bevacizumab). Read More
While the SEC is still trying to wrap its regulatory arms around the Jumpstart Our Business Startups (JOBS) Act, biopharma is pushing for more financial reforms to loosen the bureaucratic chokehold that threatens to strangle small biotechs. Read More
Alkermes plc posted its most impressive quarter so far since last fall's acquisition of Elan Corp. plc's drug delivery unit and relocation of its headquarters to Dublin, Ireland, reporting total revenues of $152.2 million, a 146 percent jump over the same three-month period in 2011. Read More
Four months after passing on an opportunity to pursue Phase III trials of its hepatitis C drug GS-7977 in combination with Bristol-Myers Squibb Co.'s daclatasvir, Gilead Sciences Inc. has confirmed that it will go it alone instead, pressing ahead with its in-house NS5A inhibitor GS-5885. Read More
Clinicians from Brigham and Women's Hospital have reported that two of their patients no longer have detectable HIV in their bodies at two years and four years, respectively, after receiving bone marrow transplants. German clinicians have already presorted on one such patient, the so-called Berlin patient. Read More
